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Previously,  the  Fiji  Pneumococcal  Project  (FiPP)  evaluated  reduced  dose  immunization  schedules  that
incorporated  pneumococcal  protein  conjugate  and/or  polysaccharide  vaccine  (PCV7  and  23vPPV,  respec-
tively). Immune  hyporesponsiveness  was  observed  in  children  vaccinated  with  23vPPV  at 12 months  of
age compared  with  children  who  did  not  receive  23vPPV.
Here  we  assess  the  long-term  impact  of 23vPPV  vaccination  on  nasopharyngeal  carriage  rates  and
densities  of  Streptococcus  pneumoniae,  Haemophilus  inﬂuenzae,  Staphylococcus  aureus  and  Moraxella
catarrhalis.  Nasopharyngeal  swabs  (n =  194)  were  obtained  from  healthy  children  who  participated  in
FiPP  (now  aged  5–7  years).  S. pneumoniae  were  isolated  and  identiﬁed  by  standard  culture-based  meth-
ods, and  serotyped  using  latex  agglutination  and the  Quellung  reaction.  Carriage  rates  and  densities  of  S.
pneumoniae,  H.  inﬂuenzae,  S. aureus  and  M.  catarrhalis  were  determined  using  real-time  quantitative  PCR.
There  were  no differences  in  the  rate  or density  of S. pneumoniae,  H. inﬂuenzae  or M. catarrhalis  carriage
by  PCV7  dose  or  23vPPV  vaccination  in  the  vaccinated  participants  overall.  However,  differences  were
observed  between  the two  main  ethnic  groups:  Fijian  children  of  Indian  descent  (Indo-Fijian)  were  less
likely  to carry  S. pneumoniae,  H.  inﬂuenzae  and  M.  catarrhalis,  and there  was  evidence  of  a higher  carriage
rate  of  S. aureus  compared  with  indigenous  Fijian  (iTaukei)  children.  Polysaccharide  vaccination  appeared
to  have  effects  that  varied  between  ethnic  groups,  with  23vPPV  vaccination  associated  with  a  higher
carriage  rate of  S. aureus  in  iTaukei  children,  while  there  was  a lower  carriage  rate  of  S.  pneumoniae
associated  with  23vPPV  vaccination  in  Indo-Fijian  children.
Overall,  polysaccharide  vaccination  had no long-term  impact  on  pneumococcal  carriage,  but  may
have  impacted  on S.  aureus  carriage  and  have varying  effects  in ethnic  groups,  suggesting  current  WHO
vaccine schedule  recommendations  against  the  use of  23vPPV  in children  under  two  years  of age  are
appropriate.© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
∗ Corresponding author at: Pneumococcal Research, Murdoch Childrens Research Institute, The Royal Children’s Hospital, Flemington Road, Parkville 3052, VIC, Australia.
el.:  +61 (0)383416438.
E-mail address: catherine.satzke@mcri.edu.au (C. Satzke).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.059
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
/).
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. Introduction
Streptococcus pneumoniae (the pneumococcus) is the most com-
on  cause of pneumonia, which is responsible for an estimated
.3 million deaths annually in children under ﬁve years of age
1]. There are over 90 different serotypes of S. pneumoniae [2,3].
rior to the introduction of pneumococcal conjugate vaccines
PCVs), the vast majority of pneumococcal disease was caused
y a limited number of serotypes [4]. Nasopharyngeal carriage
f S. pneumoniae is considered a pre-requisite for the develop-
ent of pneumococcal disease [5]. The introduction of PCVs has
ed to a dramatic reduction in invasive pneumococcal disease
aused by vaccine-type S. pneumoniae [6–8]. However, in many
ettings, there has been little change in overall S. pneumoniae
arriage due to replacement of vaccine type S. pneumoniae with
on-vaccine types (serotype replacement) [9,10]. The potential
or species replacement following pneumococcal vaccination is
lso of concern, particularly given that some studies have found
 negative relationship between vaccine-type S. pneumoniae and
taphylococcus aureus carriage [11,12]. In some settings, pneumo-
occal vaccination has also affected colonization of the respiratory
athogens Moraxella catarrhalis and Haemophilus inﬂuenzae [13,14].
The Fiji Pneumococcal Project (FiPP) was a single-blind, open-
abelled randomized Phase II vaccine trial conducted in Suva,
iji, designed to identify a pneumococcal vaccination schedule
ore suited to resource-poor countries. Speciﬁcally, FiPP eval-
ated reduced dose 7-valent pneumococcal conjugate vaccine
PCV7) primary series regimes in infancy, followed by the 23-
alent pneumococcal polysaccharide vaccine (23vPPV) booster at
2 months of age [15]. One of the key ﬁndings was immune
yporesponsiveness in 23vPPV-vaccinated children compared
ith children not vaccinated with 23vPPV, observed following
hallenge with a micro-dose (20%) of 23vPPV at 17 months
f age [16]. Nasopharyngeal carriage rates of S. pneumoniae
ere unaffected by 23vPPV vaccination at the same time-point
17].
FiPP also highlighted the differences in carriage rates between
he two main ethnicities of Fiji, indigenous Fijians (iTaukei) and
ijians of Indian descent (Indo-Fijians) [18], consistent with an
arlier carriage survey in the same setting [19]. In FiPP, carriage
f S. pneumoniae, H. inﬂuenzae and M.  catarrhalis was  higher in
Taukei children than Indo-Fijian children, and higher M. catarrhalis
ensities were found in iTaukei children vaccinated with 23vPPV
ompared with iTaukei children who were not vaccinated with
3vPPV [18].
In the follow-up study to FiPP, a subset of children were enrolled
o investigate the long-term impact of 23vPPV vaccine on carriage,
mmunity and clinical outcomes. Here we report the long-term
ffect of pneumococcal vaccination on nasopharyngeal carriage
f S. pneumoniae and other respiratory pathogens, and examine
ifferences in carriage between the two main ethnicities of Fijian
hildren.
. Materials and methods
.1. Study design
The original FiPP study design is described elsewhere [15]. In
rief, healthy Fijian infants (n = 552) were randomized to receive
ither 0, 1, 2 or 3 doses of PCV7 (Prevnar®, Pﬁzer Inc., USA) at 6,
0 and/or 14 weeks, with or without a 12 month dose of 23vPPV
Pneumovax®, Merck & Co., Inc., USA). Children who  were random-
zed to receive 0 or 1 dose of PCV7 were given a catch-up dose of
his vaccine at 2 years of age. The long-term implications of the
mmune hyporesponsiveness observed at 18 months in children
eceiving 23vPPV were investigated in the Fiji follow-up study by3 (2015) 5708–5714 5709
enrolling all FiPP participants that were contactable (n = 195), now
aged 5–7 years old. One hundred and ninety ﬁve nasopharyngeal
swabs were collected, of which 194 were available for microbio-
logical analysis (Table 1). The characteristics of this subset, such as
ethnicity, gender and number of children in each group, were simi-
lar to that of FiPP (see Supplemental Table S1 and Table 2 in Russell
et al., 2010 [17]), and were similar when considering each vaccine
alone in this study (see Supplemental Table S2)—although children
who received 3 doses of PCV7 were slightly older than children who
received 2 doses of PCV7 (median age 6.21 years vs. 5.92 years,
p = 0.017). The geometric mean antibody levels in this study for
23vPPV vaccinated and 23vPPV unvaccinated children were simi-
lar to those observed in these children at 18 months of age in FiPP
(data not shown).
This study was approved by the Human Research Ethics Com-
mittee, Royal Children’s Hospital, Melbourne and the Fiji National
Research Ethics Review Committee.
2.2. Nasopharyngeal swabs
Buffered cotton nasopharyngeal swabs (Sarstedt, Australia)
were collected and transported as described previously [17], in line
with World Health Organization guidelines [20,21]. Swabs were
stored frozen in 1 ml  of skim milk tryptone glucose glycerol (STGG)
medium, and later transported on dry ice to the Pneumococcal
Research laboratory at the Murdoch Childrens Research Institute
in Melbourne, where they were stored at −80 ◦C until processing.
2.3. Culture, identiﬁcation and serotyping
Samples were cultured on Columbia horse blood agar plates con-
taining 5 g/ml of gentamicin (gHBA; Oxoid brand, Thermo Fisher
Scientiﬁc, Australia) and incubated for 36–44 h (37 ◦C, ∼5% CO2)
[22]. Two  -hemolytic colonies were randomly selected for subcul-
ture using a method previously described [22]. These colonies, plus
any additional morphologically distinct -hemolytic colonies, were
subcultured onto Columbia horse blood agar plates (HBA; Oxoid
brand, Thermo Fisher Scientiﬁc, Australia) and incubated for 24 h
(37 ◦C, ∼5% CO2).
Colonies that were optochin sensitive were presumptively iden-
tiﬁed as S. pneumoniae. Other -hemolytic colonies that were
non-susceptible to optochin (intermediate or resistant) were tested
for bile solubility and with the Phadebact® Pneumococcus test
(Boule Diagnostics AB, Huddinge, Sweden) to enable identiﬁcation.
Presumptive pneumococci were serotyped by latex agglutina-
tion using a combination of commercial reagents (Denka-Seiken
Co., Ltd., Japan) and reagents produced in-house [23,24] using
Statens Serum Institute antisera (SSI, Copenhagen, Denmark).
Equivocal reactions were conﬁrmed using the Quellung reac-
tion with antisera from SSI [25]. Isolates that were non-typeable
were tested for the presence of the lytA gene by real-time PCR
[26]. lytA-negative non-typeable isolates were excluded from
further analysis. lytA-positive non-typeable isolates were fur-
ther examined by multilocus sequencing typing (MLST) [27].
MLST allelic proﬁles were submitted to the S. pneumoniae MLST
database (http://pubmlst.org/spneumoniae/) sited at the Univer-
sity of Oxford [28] where new sequence types (STs) were assigned
for those isolates with allelic proﬁles not matching any existing
ST. A serotype 14-speciﬁc PCR [29] was used to test non-typeable
isolates that had MLST STs associated with serotype 14.2.4. Quantitative PCR
Genomic DNA was extracted from 100 l STGG using the QIAmp
DNA Minikit (Qiagen) as previously described [18]. S. pneumoniae,
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Table 1
Previous pneumococcal vaccinations received by the 194 participants in this study.
Group Initial PCV7 doses Initial PCV7 dose
timing (wks)
23vPPV (12 mo)  End of FiPP PCV7
dose*
Total PCV7 doses NP swabs collected
in  this study (n)
A 3 6, 10, 14 − 0 3 26
B  3 6, 10, 14 + 0 3 28
C  2 6 and 14 − 0 2 25
D  2 6 and 14 + 0 2 30
E  1 14 − 1 2 15
F  1 14 + 1 2 25
G  0 None + 1 1 19
H  0 None − 1 1 26
* PCV7 dose given at 2 years of age.
Table 2
MLST allelic proﬁles for the non-typeable (NT) isolates.
Isolate aroE gdh gki recP spi xpt ddl ST Associated serotypes**
0534–01 8 37 9 29 2 12 14 1619 19A, NT
0075–01 1 5 4 5 5 1 229 10183* Closest match ST9 (14)
0119–04 8 29 4 15 17 12 31 1106 14, NT
0541–01 8 29 4 15 17 12 31 1106 14, NT
0051–01 8 29 4 15 17 12 31 1106 14, NT
0173–01 7 139 4 8 13 38 216 10184*
0586–02 8 37 9 29 2 12 53 344 NT
0586–01  8 37 9 29 2 12 31 10185* Closest match ST344 (NT)
0918–03 8 37 9 29 2 12 31 10185* Closest match ST344 (NT)
0598–03 8 37 9 29 2 12 31 10185* Closest match ST344 (NT)
0009–01 8 37 9 29 2 12 31 10185* Closest match ST344 (NT)
0500–01 213 5 223 1 17 1 14 10182* Closest match ST3516 (19F)
0082–03 16 9 193 226 6 20 5 10181*
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** Serotypes associated with ST or closest match for newly identiﬁed STs.
. aureus,  M.  catarrhalis and H. inﬂuenzae were examined by real-
ime quantitative PCR (qPCR) using two duplex assays [18], see
upplemental Table S4. Bacterial densities were determined using
 standard curve from a dilution series prepared with genomic DNA
rom reference isolates [18].
.5. Statistical analysis
Logistic regression was used to examine the impact of PCV7 (1,
 or 3 doses) and 23vPPV (0 or 1 dose) on carriage of S. pneumoniae,
. inﬂuenzae,  S. aureus and M.  catarrhalis,  with each species exam-
ned in separate models. To determine if the effect of 23vPPV was
ependent on the number of doses of PCV7 received, an interaction
etween 23vPPV and the number of doses of PCV7 was also con-
idered in each model. Regression models were used to examine
he effect of PCV7 and 23vPPV on density, with bacterial density
ata log transformed prior to analysis. To examine bacterial associ-
tions, logistic regression models were ﬁtted to determine the odds
f carrying one bacterial species given carriage of another species.
or analyses of vaccine-type carriage culture data were used, while
PCR data were used for all other analyses.
For ethnicity based analyses, due to the small number of indi-
iduals who were of ‘other’ ethnicity (n = 6), only those of iTaukei
n = 139) and Indo-Fijian (n = 49) ethnicity were included. Where
ero counts were observed, exact logistic regression was used
o obtain the median unbiased estimate of the odds ratio [30].
haracteristics of study participants by ethnic group are shown
n Supplemental Table S3. An adjusted analyses for potential con-
ounders for comparisons between iTaukei and Indo-Fijian children
as considered, however as these variables are considered inter-
ediary steps in the relationship between ethnicity and carriage,
nd not true confounders, this analysis was not conducted [31].
Where analyses examine vaccine-type serotypes, only those
erotypes included in each vaccine were considered (potentiallycross-reactive serotypes were considered non-vaccine type). As
serotype 15B is present in 23vPPV, 15B and 15C were considered
separately despite the potential of these serotypes to interconvert
[32]. Analyses were conducted using the Stata 12 software (release
12; StataCorp, College Station, TX, USA).
3. Results
Of the 194 swabs tested, 85 (44%) were positive for S. pneumo-
niae, 99 (51%) for H. inﬂuenzae,  142 (73%) for M. catarrhalis and 53
(27%) for S. aureus by qPCR. Using culture, 88 (45%) swabs contained
pneumococci, of which 13 (15%) contained PCV7 vaccine types, 37
(42%) contained 23vPPV types (including PCV7 types), and 51 (58%)
only contained serotypes absent from either vaccine. Overall, 103
isolates were identiﬁed; non-typeable S. pneumoniae were most
common (n = 13, 12.6%), followed by serotypes 11A (n = 10, 9.7%),
6A (n = 8, 7.8%) and 16F (n = 7, 6.8%) (Fig. 1).
3.1. Non-typeable S. pneumoniae
All 19 -hemolytic isolates that were presumptively identiﬁed
as non-typeable S. pneumoniae were tested by lytA real-time PCR.
Six were negative for the lytA gene and were designated as non-
S. pneumoniae. The remaining 13 isolates were examined by MLST
(Table 2) and represented eight STs, including ﬁve new STs. Four
isolates had STs commonly associated with serotype 14; however,
they were negative when tested using a serotype 14-speciﬁc PCR
and thus designated non-typeable pneumococci.
3.2. Impact of pneumococcal vaccination on nasopharyngeal
carriage rates and densitiesNone of the models considering an interaction term between
23vPPV and PCV7 doses showed signiﬁcant interaction (each
p > 0.05; details not shown). Adjustment for PCV7 doses and
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Fig. 1. Pneumococcal serotypes (identiﬁed by culture-based methods) carried in study participants as a percentage of total isolates identiﬁed (n = 102). NT = non-typeable,
other  (each serotype represents ∼1% of total isolates) = 1*, 3*, 9A, 10A*, 10B, 15A, 18C**, 19B, 19 C, 35B, 35 C, 38 (**PCV7 types, *non-PCV7 23vPPV types).
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igniﬁcant difference by vaccination status in overall S. pneumoniae, PCV7 vaccine t
3vPPV/PCV7 dose interaction gave results that were similar to the
esults from unadjusted analysis of the effect of 23vPPV. As such
nadjusted results are presented unless speciﬁed.
The number of PCV7 doses received had no statistically sig-
iﬁcant impact on pneumococcal carriage rate or density (each
 > 0.05). Similarly, there were no differences in the rate or den-
ity of pneumococcal carriage between 23vPPV recipients and
on-recipients, regardless of adjustment for the number of PCV7
oses received (each p > 0.05). There were no statistically signiﬁ-
ant differences in the carriage rates (Fig. 2) or densities of vaccine
ype (PCV7 and 23vPPV) carriage by doses of either vaccine (each
 > 0.05).
We  found no long-term impact of 23vPPV or PCV7 vaccination
n H. inﬂuenzae carriage rates or densities. S. aureus carriage rates
ere higher in 23vPPV recipients (OR = 2.41, 95% CI (1.24, 4.68);
 = 0.010) compared with children that did not receive 23vPPV,
ith 36 (35%) 23vPPV recipients carrying S. aureus compared with
7 (18%) children that did not receive 23vPPV. M. catarrhalis den-
ity was higher (p = 0.036) in children that received 1 dose of PCV7
median density 1.51 × 105 cfu/ml) compared with children who
eceived 3 doses of PCV7 (median density 1.38 × 106 cfu/ml).ge identiﬁed by culture) by vaccination status in children in Fiji aged 5–7 years. No
 23vPPV vaccine type carriage.
3.3. Bacterial associations
Carriage of S. pneumoniae was positively associated with
carriage of H. inﬂuenzae and M. catarrhalis (Table 3). Positive associ-
ations were also observed between H. inﬂuenzae and M.  catarrhalis.
A negative association, where carriage of one species is less likely to
occur given the presence of another species, was observed between
S. aureus and M. catarrhalis,  and between S. aureus and H. inﬂuenzae.
3.4. Effect of ethnicity
Overall, 1 (2%) Indo-Fijian child and 35 (25%) iTaukei children
were carrying 23vPPV vaccine types, with 1 (2%) Indo-Fijian child
and 11 (8%) Indo-Fijian children carrying PCV7 vaccine types. Sig-
niﬁcant differences in overall carriage rates were found between
the two  main ethnicities. Indo-Fijian children had lower odds of
carrying S. pneumoniae (OR = 0.20, 95% CI (0.09, 0.44); p < 0.001),
H. inﬂuenzae (OR = 0.18, 95% CI (0.08, 0.38); p < 0.001) and M.
catarrhalis (OR = 0.12, 95% CI (0.06, 0.24); p < 0.001), and higher
odds of carrying S. aureus (OR = 2.31, 95% CI (1.15, 4.61); p = 0.018)
compared with iTaukei children. Carriage densities between the
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Table 3
Bacterial associations: odds ratio (OR) of carriage of one species given carriage of another as determined by qPCR.
Overall H. inﬂuenzae M. catarrhalis S. aureus
n (%) n (%) OR (95% CI); p-value n (%) OR (95% CI); p-value n (%) OR (95% CI); p-value
S. pneumoniae (all serotypes) 85 (44) 65 (34) 7.17 (3.76, 13.66); p < 0.001* 72 (37) 3.09 (1.52, 6.27); p = 0.002* 19 (10) 0.64 (0.33, 1.22); p = 0.172
S.  pneumoniae (PCV7 VT) 13 (7) 9 (5) 2.28 (0.68, 7.65); p = 0.184 10 (5) 1.24 (0.33, 4.68); p = 0.754 3 (2) 0.79 (0.21, 2.97); p = 0.723
S.  pneumoniae (23vPPV VT) 37 (19) 26 (13) 2.72 (1.26, 5.88); p = 0.011* 33 (17) 3.63 (1.22, 10.83); p = 0.021* 8 (4) 0.69 (0.29, 1.62); p = 0.389
H.  inﬂuenzae 99 (51) 84 (43) 3.57 (1.80, 7.10); p < 0.001* 20 (10) 0.48 (0.25, 0.91); p = 0.024*
M.  catarrhalis 142 (73) 29 (15) 0.30 (0.15, 0.59); p = 0.001*
S. aureus 53 (27)
* Signiﬁcant (p < 0.05); VT = vaccine type; percentage is out of the 194 participants.
Table 4
Odds ratios for carriage of S. pneumoniae, H. inﬂuenzae,  M.  catarrhalis and S. aureus in iTaukei and Indo-Fijian 23vPPV recipients compared with 23vPPV non-recipients as
determined by qPCR.
All no 23vPPV recipients 23vPPV recipients OR 95% CI p-Value
iTaukei (n = 139***) S. pneumoniae n (%) 74 (53) 35 (55) 39 (52) 0.90 0.46, 1.75 0.752
H.  inﬂuenzae n (%) 86 (62) 41 (64) 45 (60) 0.84 0.42, 1.68 0.623
M.  catarrhalis n (%) 119 (86) 59 (92) 60 (79) 0.34 0.12, 0.99 0.048**
S. aureus n (%) 32 (23) 6 (9) 26 (35) 5.13 1.95, 13.47 0.001*
Indo-Fijian (n = 49****) S. pneumoniae n (%) 9 (18) 9 (39) 0 (0) 0.06***** 0.00, 0.45 0.003*
H. inﬂuenzae n (%) 11 (22) 5 (22) 6 (23) 1.48 0.39, 5.71 0.567
M.  catarrhalis n (%) 20 (41) 13 (57) 7 (27) 0.44 0.14, 1.42 0.168
S.  aureus n (%) 20 (41) 11 (48) 9 (35) 0.88 0.28, 2.75 0.821
* Signiﬁcant (p < 0.05).
** Not signiﬁcant after adjusting for PCV7 dose, with (p = 0.310) or without (p = 0.053) including interaction between PCV7 and 23vPPV.
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**** Of the 49 Indo-Fijian children, there were 26 with 23vPPV and 23 with no 23vP
**** Exact logistic regression used to obtain the median unbiased estimate due to th
wo ethnic groups differed for M.  catarrhalis (median density of
.00 × 105 cfu/ml for iTaukei vs 9.49 × 104 cfu/ml for Indo-Fijians;
 = 0.008) but not for the other three bacterial species.
No Indo-Fijian 23vPPV recipients were found to carry S. pneumo-
iae, while 39% of Indo-Fijian children who did not receive 23vPPV
ere carriers (Table 4). There was no evidence of a difference in the
dds of carrying S. pneumoniae among iTaukei who  did and did not
eceive 23vPPV; however, the odds of carrying S. aureus were signif-
cantly higher in 23vPPV recipients compared with non-recipients
Table 4). There was no effect of 23vPPV vaccination on carriage
f H. inﬂuenzae or M.  catarrhalis (after adjustment for PCV7 doses
eceived) for either ethnic group. There was no evidence that PCV7
ad an effect on carriage for any of the bacterial species by ethnic
roup.
. Discussion
Immune hyporesponsiveness following pneumococcal polysac-
haride vaccination at 12 months of age was described previously
or the children in this study [16]. The long-term implications
f hyporesponsiveness on nasopharyngeal carriage are unknown,
espite concerns that this may  lead to increased pneumococcal dis-
ase susceptibility in these children. Currently the World Health
rganization does not recommend 23vPPV to children under the
ge of two years based on immunological ﬁndings [33], how-
ver there are limited data on the effects of 23vPPV vaccination
n nasopharyngeal carriage in children and no published studies
ooking at long-term effects. In this study, we found no long-
erm impact of 23vPPV on S. pneumoniae carriage. Early studies of
ther pneumococcal polysaccharide vaccines reported no effect of
olysaccharide vaccination on nasopharyngeal carriage of S. pneu-
oniae [34–36]. More recently, two short-term studies, the original
iPP study [17] and another study in children aged 1–7 years with
cute otitis media [37], also found that 23vPPV vaccination had no
ffect on carriage. count.
Of the 88 children in our study carrying pneumococci, 37 (42%)
were carrying serotypes included in 23vPPV, a coverage rate which
may  suggest a justiﬁcation for the use of 23vPPV in this popula-
tion. However, 21 of the 41 (51%) children vaccinated with 23vPPV
were carrying 23vPPV types compared with 16 of the 47 (34%) chil-
dren not vaccinated with 23vPPV, suggesting that 23vPPV does not
reduce carriage of 23vPPV serotypes in the long-term.
In contrast to the original FiPP study, which found a dose-
dependent effect of PCV7 on pneumococcal carriage [17], we found
no long-term differences in pneumococcal carriage in children who
received 1, 2 or 3 PCV7 doses. However, due to the catch-up dose at
the end of the previous study, there was  no PCV7-unvaccinated
group in this study to serve as a comparator. PCV7 vaccination
appears to have eliminated carriage for three of the seven PCV7
serotypes (serotypes 4, 6B and 9V).
Consistent with previous studies, we found differences in car-
riage between the two  main ethnic groups in Fiji [18,19]. These
differences were most striking when examining the effect of
23vPPV vaccination after stratifying by ethnicity, as the association
between 23vPPV receipt and increased S. aureus carriage appears
to only occur in iTaukei children. Additionally, there was  evidence
to suggest that 23vPPV may  have reduced S. pneumoniae carriage
in Indo-Fijians. In FiPP, there was  no evidence that 23vPPV vaccina-
tion had varying effects on carriage rates in the two  ethnic groups
but iTaukei 23vPPV recipients had higher carriage densities of M.
catarrhalis [18], ﬁndings not replicated in our study. However, the
carriage rate of S. aureus was  very low in FiPP (3.3%, typical for 17-
month old children) compared with our study (27%). Additionally,
analyses of carriage for FiPP were limited to the groups given 3
doses of PCV7 with 23vPPV, 3 doses of PCV7 without 23vPPV and
the unvaccinated control group, whereas our study used data from
all groups.Ethnic differences in susceptibilities to infectious diseases such
as tuberculosis, dengue fever and malaria [38–40], as well as the
immune response to rubella vaccination [41], have been observed
in other populations. There was no difference between iTaukei and
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ndo-Fijian children in this study for many pneumococcal carriage
isk factors such as antibiotic use and exposure to cigarette smoke
42], although household income was higher for Indo-Fijian chil-
ren (median weekly income ($US) $82.50 vs. $57.75, p = 0.001).
hile socio-economic status is a risk factor for pneumococcal
arriage [43], the differences in carriage between iTaukei and Indo-
ijian children in our study are consistent with previous studies in
iji [18,19], where household income levels were not different. It is
herefore unlikely that the differences observed in the two ethnic
roups in our study are attributable to economic status. The rea-
ons underpinning the differences between the two  main groups
n Fiji are unknown but maybe due to unknown household and
ocial factors, or genetic susceptibility.
Some, but not all, studies have reported increased S. aureus
arriage following PCV7 vaccination [44,45], consistent with obser-
ations of a negative relationship between carriage of S. aureus and
accine-type S. pneumoniae [13,14,46]. In this study, there was  no
lear evidence that the association between 23vPPV receipt and
ncreased S. aureus carriage in iTaukei children was due to bac-
erial interactions or species replacement given that there was
ot a corresponding reduction in vaccine-type S. pneumoniae car-
iage. Most of the bacterial interactions we found are consistent
ith other studies; such as the positive relationships between S.
neumoniae and M.  catarrhalis,  and S. pneumoniae and H. inﬂuenzae
43,47,48]. We found no association between S. aureus and S. pneu-
oniae, vaccine-type or otherwise. However, as all children were
accinated with PCV7, PCV7 vaccine-type carriage was uncom-
on. While bacterial interactions or species replacement do not
ppear to have an effect at this time point, we  have no carriage
ata between 17 months and 5–7 years of age, and it is possible
hat the changing carriage dynamics during this period may  have
layed a role that is no longer apparent.
There are limited data on the impact of 23vPPV vaccination on
. aureus carriage and so the mechanism behind this observation
s unknown. One study in children with a history of otitis media
oted higher acute otitis media attributable to S. aureus in chil-
ren vaccinated with PCV7 and 23vPPV compared with children
hat received no pneumococcal vaccination, however carriage of
. aureus was not examined [49]. The presence of pilus in S. pneu-
oniae [50] and, to a lesser degree, hydrogen peroxide-mediated
illing of S. aureus by S. pneumoniae [51] in vitro have both been
mplicated in the negative association between S. pneumoniae and S.
ureus. However, it is clear the immune system also plays an impor-
ant role as studies examining the effect of PCV in HIV-infected
nd HIV-uninfected children have shown no negative association
etween S. pneumoniae and S. aureus in the immunocompromised
hildren [52,53]. Additionally, prior S. pneumoniae colonization in
 mouse model was found to inhibit S. aureus acquisition due to
ross-reactive antibodies to a pneumococcal dehydrogenase [54].
The clinical implication of higher S. aureus carriage in iTaukei
3vPPV vaccinated individuals (compared with iTaukei children
ot vaccinated with 23vPPV) is also unclear, although our prelim-
nary analyses show no change in hospital admissions between
roups (Licciardi et al., unpublished results). However, it is pos-
ible this may  affect diseases for which hospitalization would be
nlikely, such as otitis media and skin infections. It should also
e noted that although 23vPPV was associated with higher car-
iage of S. aureus in iTaukei children, the carriage rate of S. aureus
n iTaukei 23vPPV recipients was similar to that of Indo-Fijian
hildren who did not receive 23vPPV (35% vs. 48%, respectively).
mmunologically, preliminary analyses show that there were no
ifferences in antibody levels (geometric mean antibody concen-
rations) between 23vPPV vaccinated and 23vPPV unvaccinated
hildren, and that the antibody levels seen in each ethnic group
ere similar, consistent with ﬁndings from the original FiPP study
Licciardi et al., unpublished results). Given the relatively small3 (2015) 5708–5714 5713
numbers in this study, larger studies would be required to fully
explore some observations and relationships, such as differences
in ethnicity and the impact of 23vPPV on S. aureus carriage.
We found a relatively large number of non-typeable pneumo-
cocci in this study and identiﬁed four new MLST STs. Other studies
with a similar methodology have also found a relatively large pro-
portion of non-typeables [55]. Most of our non-typeable isolates
had STs (or close matches to STs) commonly associated with non-
typeables, such as ST344. However, three were ST1106 which is
associated with serotype 14. Although previous studies have found
non-typeable isolates genetically related to serotype 14 [56,57],
further investigation of our isolates using a serotype 14-speciﬁc
PCR suggest that these isolates may  lack part of the capsule locus
or have capsule sequences that are sufﬁciently divergent that they
are not detected by the serotype 14-speciﬁc PCR.
5. Conclusions
Although 23vPPV vaccination was  associated with immune
hyporesponsiveness in children at 17 months, it had no impact on
S. pneumoniae carriage rates or densities at 17 months and no long-
term impact on S. pneumoniae carriage rates or densities in children
now aged 5–7 years. However, our data suggest that 23vPPV vac-
cination may be associated with higher S. aureus carriage, and may
have varying effects in different ethnic groups. Despite observing
no long-term impact on S. pneumoniae carriage rates or density,
23vPPV vaccination results in immune hyporesponsiveness, has
potential long-term effects on S. aureus carriage, and there is a lack
of evidence showing a clear beneﬁt of using 23vPPV in children
under two  years of age. As such, current guidelines recommen-
ding against the use of 23vPPV in children under 2 years of age
are appropriate.
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